RIGL Earnings Rigel Pharmaceuticals Inc
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–44 of 44
| Q2 2026 | 2026-06-30 | 0.88 | 2026-08-04 | 10-Q |
| Q1 2026 | 2026-03-31 | 0.44 | 2026-05-05 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | 14.11 | 2026-03-03 | 10-K |
| FY 2025 | 2025-12-31 | 19.48 | 2026-03-03 | 10-K |
| Q3 2025 | 2025-09-30 | 1.46 | 2025-11-04 | 10-Q |
| Q2 2025 | 2025-06-30 | 3.28 | 2025-08-05 | 10-Q |
| Q1 2025 | 2025-03-31 | 0.63 | 2025-05-06 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | 0.82 | 2025-03-04 | 10-K |
| FY 2024 | 2024-12-31 | 0.99 | 2025-03-04 | 10-K |
| Q3 2024 | 2024-09-30 | 0.70 | 2024-11-07 | 10-Q |
| Q2 2024 | 2024-06-30 | -0.06 | 2024-08-06 | 10-Q |
| Q1 2024 | 2024-03-31 | -0.47 | 2024-05-07 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | 0.07 | 2024-03-05 | 10-K |
| FY 2023 | 2023-12-31 | -1.44 | 2024-03-05 | 10-K |
| Q3 2023 | 2023-09-30 | -0.33 | 2023-11-07 | 10-Q |
| Q2 2023 | 2023-06-30 | -0.38 | 2023-08-01 | 10-Q |
| Q1 2023 | 2023-03-31 | -0.80 | 2023-05-02 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | 0.06 | 2023-03-07 | 10-K |
| FY 2022 | 2022-12-31 | -3.44 | 2023-03-07 | 10-K |
| Q3 2022 | 2022-09-30 | -1.10 | 2022-11-03 | 10-Q |
| Q2 2022 | 2022-06-30 | -0.80 | 2022-08-02 | 10-Q |
| Q1 2022 | 2022-03-31 | -1.60 | 2022-05-03 | 10-Q |
| Q4 2021 (derived) | 2021-12-31 | -1.30 | 2022-03-01 | 10-K |
| FY 2021 | 2021-12-31 | -1.10 | 2022-03-01 | 10-K |
| Q3 2021 | 2021-09-30 | -1.20 | 2021-11-02 | 10-Q |
| Q2 2021 | 2021-06-30 | -0.80 | 2021-08-03 | 10-Q |
| Q1 2021 | 2021-03-31 | 2.20 | 2021-05-05 | 10-Q |
| Q4 2020 (derived) | 2020-12-31 | -1.30 | — | — |
| FY 2020 | 2020-12-31 | -1.80 | — | — |
| Q3 2020 | 2020-09-30 | -0.80 | — | — |
| Q2 2020 | 2020-06-30 | -1.00 | — | — |
| Q1 2020 | 2020-03-31 | 1.30 | 2020-05-05 | 10-Q |
| FY 2019 | 2019-12-31 | -4.00 | — | — |
| Q1 2019 | 2019-03-31 | -1.10 | — | — |
| FY 2012 | 2012-12-31 | -13.20 | 2013-03-05 | 10-K |
| Q3 2012 | 2012-09-30 | -3.60 | 2012-11-06 | 10-Q |
| Q2 2012 | 2012-06-30 | -3.50 | 2012-08-07 | 10-Q |
| FY 2011 | 2011-12-31 | -13.60 | 2012-03-06 | 10-K |
| Q3 2011 | 2011-09-30 | -2.50 | 2011-11-01 | 10-Q |
| Q2 2011 | 2011-06-30 | -3.70 | 2011-08-02 | 10-Q |
| FY 2010 | 2010-12-31 | 7.20 | — | — |
| Q3 2010 | 2010-09-30 | 9.60 | — | — |
| Q2 2010 | 2010-06-30 | 5.10 | — | — |
| FY 2009 | 2009-12-31 | -27.30 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.